A novel ESIPT based fluorescent probe for L-BPA sensing
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Boron Compounds in Chemistry · Organoboron and organosilicon chemistry · Boron and Carbon Nanomaterials Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Redox mechanisms underlying the cytostatic effects of boric acid on cancer Cells-An issue still open10.3390/antiox12061302 ↗
2. Recent developments in organoboron chemistry: old dogs, new tricks10.1016/j.chempr.2017.05.008 ↗
3. Boron chemicals in drug discovery and development: synthesis and medicinal perspective10.3390/molecules27092615 ↗
4. Boron in drug design: recent advances in the development of new therapeutic agents10.1016/j.ejmech.2019.06.092 ↗
5. Spotlight on tavaborole for the treatment of onychomycosis
6. Development of the proteasome inhibitor Velcade (Bortezomib)10.1081/CNV-120030218 ↗
7. T. Robak, H. Huang, J. Jin, J. Zhu, T. Liu, O. Samoilova, H. Pylypenko, G. Verhoef, N. Siritanaratkul, E. Osmanov, J. Alexeeva, J. Pereira, J. Drach, J. Mayer, X. Hong, R. Okamoto, L. Pei, B. Rooney, H. van de Velde, F. Cavalli, Bortezomib-Based therapy for newly diagnosed mantle-cell lymphoma, N Engl J Med 372(10) 944-953.10.1056/NEJMoa1412096 ↗
8. Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-Year carcinogenicity studies10.1177/1091581814545245 ↗
9. Ixazomib – the first oral proteasome inhibitor10.1080/10428194.2018.1523398 ↗
10. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection10.1111/exd.14722 ↗
11. Structural basis and binding kinetics of vaborbactam in class A β-Lactamase inhibition10.1128/AAC.00398-20 ↗
12. Proposal of recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for neutron capture therapy10.1093/jrr/rrad064 ↗
13. Identification of borinic esters as inhibitors of bacterial cell growth and bacterial methyltransferases, CcrM and MenH10.1021/jm050676a ↗
14. Drugs for BNCT: BSH and BPA
15. Boron chemistry for medical applications10.3390/molecules25040828 ↗
16. Handbook of Boron science
17. Gao · 2018 · 371
18. Hosmane · 2011
19. Advancements in the synthesis and biological properties of carboranes and high-boron related compounds: a comprehensive exploration with emphasis on BNCT applications
20. Boron neutron capture therapy of cancer: current status and future prospects10.1158/1078-0432.CCR-05-0035 ↗
21. Clinical viability of Boron Neutron capture therapy for personalized radiation treatment10.3390/cancers14122865 ↗
22. Molecular mechanisms of specific cellular DNA damage response and repair induced by the mixed radiation field during Boron neutron capture therapy10.3389/fonc.2021.676575 ↗
23. Application of a lab-made ternary Fe-Cr-Al coil vaporizer coupled to ICP OES for boron determination in powdered food after the sample preparation in alkaline media10.1016/j.microc.2020.104875 ↗
24. Trace analysis of potentially mutagenic boronic acids and esters in drug substance by ICP-MS10.1021/acs.oprd.6b00325 ↗
25. Fluorescent sensing for boronic acid derivatives: design, synthesis, mechanism, application and perspective in Boron Neutron Capture Therapy (BNCT)10.1016/j.dyepig.2024.112561 ↗
26. Synthesis and mechanistic investigation of BPA fluorescent probes targeting BPA for potential application in Boron Neutron Capture Therapy (BNCT)10.1016/j.saa.2024.125318 ↗
27. Li · 2022
28. Imine–Amine tautomerism vs keto–enol tautomerism: acceptor basicity dominates over acceptor electronegativity in the ESIPT process through a six-membered intramolecular H-Bonded network10.1021/acs.jpca.9b08646 ↗
29. Calculation of the detection limits by explicit expressions10.1016/j.apradiso.2017.02.014 ↗
30. Development of a 2 - (2 - Hydroxyphenyl) -1H-benzimidazole-Based fluorescence sensor targeting boronic acids for versatile application in boron neutron capture therapy10.3390/cancers15061862 ↗
31. Fluorescence quenchers for hydrazone and oxime orthogonal bioconjugation10.1021/bc300344b ↗
32. Peripheral substituent effect on ‘turn-on’ fluorescence of BODIPY derivatives for sensing benzene moieties10.1016/j.molstruc.2024.140253 ↗
33. An environmentally sensitive zinc-selective two-photon NIR fluorescent turn-on probe and zinc sensing in stroke10.1016/j.jpha.2023.11.010 ↗
34. An sp-hybridized all-carboatomic ring, cyclo[18]carbon: electronic structure, electronic spectrum, and optical nonlinearity10.1016/j.carbon.2020.05.023 ↗
35. Multiwfn: a multifunctional wavefunction analyzer10.1002/jcc.22885 ↗
36. Red-shifted optical absorption induced by donor–acceptor–donor π-extended dibenzalacetone derivatives10.1039/D4RA07256A ↗
37. Enlarging the stokes shift by weakening the π-Conjugation of cyanines for high signal-to-noise ratiometric imaging
38. Pharamacokinetic modeling for boronophenylalanine-fructose mediated neutron capture therapy: 10 B concentration predictions and dosimetric consequences